Shares of Hikma Pharmaceuticals PLC HIK inched down 0.93% to £18.09 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising ...

Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Shares of Hikma Pharmaceuticals PLC HIK inched up 0.33% to £18.37 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.65% to ...

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday said it is on track to deliver "another strong performance" following trading to date, and reiterates its full-year revenue expectations.

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma ... and the UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), Hikma does not undertake ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and EuropeCompleted ZYNQUISTA™ FDA ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024,... Jazz Pharmaceuticals Announces Pricing of ...